Therefore, the present study determined the effects of DOX (40 mg/kg intraperitoneal) (23) or MLX (2 mg/kg intraperitoneal) (25) monotherapy and combination therapy on the levels of TNF-α, IL-4, IL-6, IL-10, IL-17, BDNF, MMP-3, TIMP-3 and COX-2 in the brain tissues of rats with brain inflammation induced by intracranial LPS administration. This evidence concerns the gene IL17A and brain inflammatory disease.